{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:20:07Z","timestamp":1783099207626,"version":"3.54.6"},"reference-count":308,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.cardfail.2019.09.002","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T18:57:45Z","timestamp":1568833065000},"page":"986-1003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction"],"prefix":"10.1016","volume":"25","author":[{"given":"Milton","family":"Packer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2019.09.002_bib0001","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/eurjhf\/hfs130","article-title":"Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction","volume":"14","author":"Santhanakrishnan","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0002","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jacc.2018.06.050","article-title":"Identifying pathophysiological mechanisms in heart failure with reduced versus preserved ejection fraction","volume":"72","author":"Tromp","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0003","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0004","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/ejhf.1294","article-title":"The epicardial adipose inflammatory triad: coronary atherosclerosis, atrial fibrillation, and heart failure with a preserved ejection fraction","volume":"20","author":"Packer","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0005","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1093\/eurheartj\/ehy531","article-title":"Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF","volume":"39","author":"Shah","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0006","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/eurheartj\/ehv514","article-title":"Magnetic resonance imaging of atrial fibrosis: redefining atrial fibrillation to a syndrome","volume":"38","author":"Gal","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0007","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0008","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jacc.2006.10.061","article-title":"Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study","volume":"49","author":"Maurer","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0009","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2014.08.036","article-title":"Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction","volume":"64","author":"Mentz","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201836","article-title":"High-sensitivity C-reactive protein in heart failure with preserved ejection fraction","volume":"13","author":"DuBrock","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0011","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0012","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0013","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0014","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0015","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0016","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10741-014-9453-8","article-title":"Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis","volume":"20","author":"Bavishi","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0017","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","article-title":"Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure)","volume":"53","author":"van Veldhuisen","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0018","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0019","unstructured":"Solomon SD, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund P, Boytsov SA, Colet JC, Cleland J, Duengen H-D, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP, McMurray JJV, PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med, in press."},{"key":"10.1016\/j.cardfail.2019.09.002_bib0020","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0021","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jacc.2013.06.043","article-title":"Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial","volume":"62","author":"Kosmala","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0022","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1161\/CIRCULATIONAHA.115.017119","article-title":"Effect of selective heart rate slowing in heart failure with preserved ejection fraction","volume":"132","author":"Pal","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0023","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1002\/oby.20149","article-title":"Epicardial adipose tissue assessed by cardiac magnetic resonance imaging in patients with heart failure due to dilated cardiomyopathy","volume":"21","author":"Doesch","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0024","doi-asserted-by":"crossref","first-page":"891","DOI":"10.7150\/ijms.19854","article-title":"Expression of epicardial adipose tissue thermogenic genes in patients with reduced and preserved ejection fraction heart failure","volume":"14","author":"P\u00e9rez-Belmonte","year":"2017","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0025","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/1756-185X.12820","article-title":"Risk of incident atrial fibrillation in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"20","author":"Ungprasert","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0026","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijcard.2018.10.024","article-title":"Ankylosing spondylitis: a novel risk factor for atrial fibrillation\u2014a nationwide population-based study","volume":"275","author":"Moon","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0027","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1080\/09546634.2016.1255703","article-title":"Psoriasis increases risk of new-onset atrial fibrillation: a systematic review and meta-analysis of prospective observational studies","volume":"28","author":"Upala","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0028","first-page":"313","article-title":"Incident atrial fibrillation in systemic sclerosis: the predictive role of B-type natriuretic peptide","volume":"55","author":"Giallafos","year":"2014","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0029","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bcp.13837","article-title":"Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review: implications for anticoagulant and antiarrhythmic therapy","volume":"85","author":"Pastori","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jjcc.2019.03.009","article-title":"Risk of cardiac arrhythmias in patients with chronic hepatitis B and C infections: a 13-year nationwide population-based study","volume":"74","author":"Wu","year":"2019","journal-title":"J Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0031","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/europace\/eut312","article-title":"Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease: a nationwide study","volume":"16","author":"Kristensen","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0032","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jacc.2010.02.029","article-title":"The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study)","volume":"55","author":"Tedrow","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0033","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s11606-010-1340-y","article-title":"Diabetes mellitus, glycemic control, and risk of atrial fibrillation","volume":"25","author":"Dublin","year":"2010","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0034","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/HYPERTENSIONAHA.117.10596","article-title":"Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term","volume":"71","author":"Rossi","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0035","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejim.2018.02.019","article-title":"Risk factors for the development of incident atrial fibrillation in patients with cardiac implantable electronic devices","volume":"52","author":"Miyazawa","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0036","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijcard.2017.03.108","article-title":"Five-year changes in cardiac structure and function in patients with rheumatoid arthritis compared with the general population","volume":"240","author":"Davis","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0037","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3899\/jrheum.100979","article-title":"The influence of rheumatoid arthritis disease characteristics on heart failure","volume":"38","author":"Myasoedova","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0038","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.semarthrit.2014.02.004","article-title":"Diastolic left ventricular dysfunction in ankylosing spondylitis: a systematic review and meta-analysis","volume":"44","author":"Heslinga","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0039","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3340\/jkns.2018.0110","article-title":"Association of congestive heart Failure and death with ankylosing spondylitis: a nationwide longitudinal cohort study in Korea","volume":"62","author":"Bae","year":"2019","journal-title":"J Korean Neurosurg Soc"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0040","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.5114\/amsad.2016.64165","article-title":"Assessment of subclinical cardiac damage in chronic plaque psoriasis patients: a case control study","volume":"1","author":"Ozden","year":"2016","journal-title":"Arch Med Sci Atheroscler Dis"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0041","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0042","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.semarthrit.2019.02.005","article-title":"Myocardial fibrosis detected by magnetic resonance imaging, elevated U-CRP and higher mRSS are predictors of cardiovascular complications in systemic sclerosis (SSc) patients","volume":"49","author":"Rodr\u00edguez-Reyna","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0043","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamacardio.2017.0264","article-title":"Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the Veterans Aging Cohort Study","volume":"2","author":"Freiberg","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0044","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016179","article-title":"The impact of chronic hepatitis B infection on major adverse cardiovascular events and all-cause mortality in patients with diabetes: a nationwide population-based study from Taiwan","volume":"7","author":"Kuo","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mvr.2014.08.003","article-title":"Impaired coronary microvascular and left ventricular diastolic function in patients with inflammatory bowel disease","volume":"97","author":"Caliskan","year":"2015","journal-title":"Microvasc Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0046","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.cgh.2018.04.031","article-title":"Increased risk of acute myocardial infarction and heart failure in patients with inflammatory bowel diseases","volume":"16","author":"Aniwan","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0047","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2337\/dci17-0052","article-title":"Heart failure: the most important, preventable, and treatable cardiovascular complication of type 2 diabetes","volume":"41","author":"Packer","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0048","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0049","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1161\/CIRCULATIONAHA.111.039586","article-title":"Secretory products from epicardial adipose tissue of patients with type 2 diabetes mellitus induce cardiomyocyte dysfunction","volume":"126","author":"Greulich","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0050","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4314\/ahs.v15i2.23","article-title":"Epicardial fat thickness in patients with rheumatoid arthritis","volume":"15","author":"Fatma","year":"2015","journal-title":"Afr Health Sci"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0051","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10067-014-2568-4","article-title":"Epicardial adipose tissue thickness in patients with ankylosing spondylitis","volume":"34","author":"Resorlu","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0052","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.acra.2017.07.003","article-title":"Increased epicardial fat volume is independently associated with the presence and severity of systemic sclerosis","volume":"24","author":"Long","year":"2017","journal-title":"Acad Radiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0053","doi-asserted-by":"crossref","first-page":"641","DOI":"10.4103\/ijem.IJEM_34_18","article-title":"Epicardial adipose tissue thickness and its correlation with metabolic risk parameters in people living with HIV: a RIMS study","volume":"22","author":"Devi","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0054","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.7863\/ultra.14.09040","article-title":"Epicardial adipose tissue is increased in patients with inflammatory bowel disease","volume":"35","author":"Uysal","year":"2016","journal-title":"J Ultrasound Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0055","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.repc.2015.04.007","article-title":"Psoriasis strikes back! Epicardial adipose tissue: another contributor to the higher cardiovascular risk in psoriasis","volume":"34","author":"Raposo","year":"2015","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0056","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1089\/met.2013.0107","article-title":"The relationship between epicardial fat and indices of obesity and the metabolic syndrome: a systematic review and meta-analysis","volume":"12","author":"Rabkin","year":"2014","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0057","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.amjcard.2013.09.022","article-title":"Effect of type 2 diabetes mellitus on epicardial adipose tissue volume and coronary vasomotor function","volume":"113","author":"Chen","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0058","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0035-1559769","article-title":"Epicardial fat thickness and primary aldosteronism","volume":"48","author":"Iacobellis","year":"2016","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0059","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1253\/circj.CJ-18-0021","article-title":"Effect of the epicardial adipose tissue volume on the prevalence of paroxysmal and persistent atrial fibrillation","volume":"82","author":"Oba","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0060","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1038\/s41598-018-21911-y","article-title":"Human epicardial adipose tissue cTGF expression is an independent risk factor for atrial fibrillation and highly associated with atrial fibrosis","volume":"8","author":"Wang","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0061","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jcmg.2016.12.005","article-title":"Epicardial fat volume and the risk of atrial fibrillation in the general population free of cardiovascular disease","volume":"10","author":"Bos","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0062","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jacep.2018.08.014","article-title":"Electroanatomical remodeling of the atria in obesity: impact of adjacent epicardial fat","volume":"4","author":"Mahajan","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0063","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.hrthm.2018.06.025","article-title":"Association of fibrotic remodeling and cytokines\/chemokines content in epicardial adipose tissue with atrial myocardial fibrosis in patients with atrial fibrillation","volume":"15","author":"Abe","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0064","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/ejhf.1283","article-title":"Epicardial fat in heart failure patients with mid-range and preserved ejection fraction","volume":"20","author":"van Woerden","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0065","doi-asserted-by":"crossref","first-page":"e3912","DOI":"10.1097\/MD.0000000000003912","article-title":"An observational study of the association among interatrial adiposity by computed tomography measure, insulin resistance, and left atrial electromechanical disturbances in heart failure","volume":"95","author":"Hung","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0066","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1749-8090-9-2","article-title":"Epicardial adipose excision slows the progression of porcine coronary atherosclerosis","volume":"9","author":"McKenney","year":"2014","journal-title":"J Cardiothorac Surg"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0067","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.jtcvs.2015.08.083","article-title":"Surgical resection of circumferential epicardial adipose tissue hypertrophy: case report and systematic review of the literature","volume":"151","author":"Smail","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0068","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/ijo.2017.239","article-title":"The relative contribution of metabolic and structural abnormalities to diastolic dysfunction in obesity","volume":"42","author":"Rayner","year":"2018","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0069","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCULATIONAHA.110.009035","article-title":"Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study","volume":"123","author":"Huxley","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0070","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa020245","article-title":"Obesity and the risk of heart failure","volume":"347","author":"Kenchaiah","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0071","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.atherosclerosis.2011.10.014","article-title":"Weight change modulates epicardial fat burden: a 4-year serial study with non-contrast computed tomography","volume":"220","author":"Nakazato","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0072","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/oby.2008.251","article-title":"Substantial changes in epicardial fat thickness after weight loss in severely obese subjects","volume":"16","author":"Iacobellis","year":"2008","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0073","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/obr.12270","article-title":"Comparison of reducing epicardial fat by exercise, diet or bariatric surgery weight loss strategies: a systematic review and meta-analysis","volume":"16","author":"Rabkin","year":"2015","journal-title":"Obes Rev"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0074","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1001\/jama.2013.280521","article-title":"Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial","volume":"310","author":"Abed","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0075","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2015.03.002","article-title":"Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY)","volume":"65","author":"Pathak","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0076","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.cardfail.2017.05.005","article-title":"Risk of heart failure in obese patients with and without bariatric surgery in Sweden-a registry-based study","volume":"23","author":"Persson","year":"2017","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0077","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.116.025629","article-title":"Weight loss and heart failure: a nationwide study of gastric bypass surgery versus intensive lifestyle treatment","volume":"135","author":"Sundstr\u00f6m","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0078","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/CIRCULATIONAHA.117.032474","article-title":"Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity","volume":"137","author":"Packer","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0079","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/oby.22038","article-title":"Bariatric surgery-induced cardiac and lipidomic changes in obesity-related heart failure with preserved ejection fraction","volume":"26","author":"Mikhalkova","year":"2018","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/DMSO.S124541","article-title":"Improvement of impaired diastolic left ventricular function after diet-induced weight reduction in severe obesity","volume":"10","author":"Karimian","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0081","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"315","author":"Kitzman","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0082","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002260","article-title":"Clinical and echocardiographic outcomes after bariatric surgery in obese patients with left ventricular systolic dysfunction","volume":"9","author":"Vest","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0083","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00011-013-0702-4","article-title":"Simvastatin inhibits cytokines in a dose response in patients with rheumatoid arthritis","volume":"63","author":"Pereira","year":"2014","journal-title":"Inflamm Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0084","first-page":"69","article-title":"The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis","volume":"33","author":"Lv","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0085","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/ard.2005.044503","article-title":"Statin therapy might be beneficial for patients with ankylosing spondylitis","volume":"65","author":"van Denderen","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0086","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4314\/njm.v19i1.54216","article-title":"The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study","volume":"19","author":"Naseri","year":"2010","journal-title":"Niger J Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0087","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.semarthrit.2015.10.013","article-title":"A review of the effects of statins in systemic sclerosis","volume":"45","author":"Ladak","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0088","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.clinre.2017.07.004","article-title":"Statin use and virus-related cirrhosis: a systemic review and meta-analysis","volume":"41","author":"Ma","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0089","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/MIB.0000000000000640","article-title":"Potential immunomodulatory effects of statins in inflammatory bowel disease","volume":"22","author":"C\u00f4t\u00e9-Daigneault","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0090","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.amjcard.2015.07.067","article-title":"Effects of atorvastatin (80 mg) therapy on quantity of epicardial adipose tissue in patients undergoing pulmonary vein isolation for atrial fibrillation","volume":"116","author":"Soucek","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0091","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijcard.2018.06.106","article-title":"Statin therapy modulates thickness and inflammatory profile of human epicardial adipose tissue","volume":"274","author":"Parisi","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0092","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2840-5-1","article-title":"Human epicardial adipose tissue expresses a patho-genic profile of adipocytokines in patients with cardiovascular disease","volume":"5","author":"Baker","year":"2006","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0093","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.jacc.2012.12.051","article-title":"Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning)","volume":"61","author":"Alexopoulos","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0094","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12872-016-0301-8","article-title":"Effects of atorvastatin on atrial remodeling in a rabbit model of atrial fibrillation produced by rapid atrial pacing","volume":"16","author":"Yang","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0095","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.hlc.2014.11.012","article-title":"Rosuvastatin attenuates atrial structural remodelling in rats with myocardial infarction through the inhibition of the p38 MAPK signalling pathway","volume":"24","author":"Wang","year":"2015","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0096","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.4238\/2013.September.10.5","article-title":"Effect of atorvastatin on left atrial function of patients with paroxysmal atrial fibrillation","volume":"12","author":"Li","year":"2013","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0097","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jacc.2007.09.063","article-title":"Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials","volume":"51","author":"Fauchier","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0098","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2125.2012.04258.x","article-title":"The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials","volume":"74","author":"Fang","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0099","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ijcard.2007.07.137","article-title":"Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies","volume":"126","author":"Liu","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0100","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/eurjhf\/hfq101","article-title":"Rosuvastatin added to standard heart failure therapy improves cardiac remodelling in heart failure rats with preserved ejection fraction","volume":"12","author":"G\u00f3mez-Garre","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0101","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1253\/circj.CJ-12-0722","article-title":"Effects of pitavastatin on cardiac structure and function and on prevention of atrial fibrillation in elderly hypertensive patients: a prospective study of 2-years' follow-up","volume":"76","author":"Warita","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0102","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.atherosclerosis.2012.03.030","article-title":"Diastolic function parameters are improved by the addition of simvastatin to enalapril-based treatment in hypertensive individuals","volume":"222","author":"Beck","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0103","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2169\/internalmedicine.46.0021","article-title":"Impact of statin therapy on systemic inflammation, left ventricular systolic and diastolic function and prognosis in low risk ischemic heart disease patients without history of congestive heart failure","volume":"46","author":"Okura","year":"2007","journal-title":"Intern Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0104","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.autneu.2018.04.006","article-title":"Differential effects of lipophilic and hydrophilic statins on muscle sympathetic nerve activity in heart failure with preserved left ventricular ejection fraction","volume":"213","author":"Tokuhisa","year":"2018","journal-title":"Auton Neurosci"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2017.12.109","article-title":"Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease","volume":"255","author":"Tsujimoto","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0106","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijcard.2016.05.027","article-title":"Heart failure in patients with human immunodeficiency virus infection: epidemiology and management disparities","volume":"218","author":"Al-Kindi","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0107","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/QAD.0000000000000547","article-title":"Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial","volume":"29","author":"Dirajlal-Fargo","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0108","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/eurheartj\/ehv072","article-title":"The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials","volume":"36","author":"Preiss","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0109","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1161\/CIRCHEARTFAILURE.115.002143","article-title":"Association between use of statins and mortality in patients with heart failure and ejection fraction of \u226550","volume":"8","author":"Alehagen","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0110","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1253\/circj.CJ-18-0639","article-title":"Effect of statins on mortality in heart failure with preserved ejection fraction without coronary artery disease: report from the JASPER Study","volume":"83","author":"Marume","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0111","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.amjcard.2018.04.027","article-title":"Comparison of effects of statin use on mortality in patients with heart failure and preserved versus reduced left ventricular ejection fraction","volume":"122","author":"Lee","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0112","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0113","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0114","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1159\/000479915","article-title":"Association between C1q\/TNF-related protein-1 levels in human plasma and epicardial adipose tissues and congestive heart failure","volume":"42","author":"Yang","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0115","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1055\/s-0042-119202","article-title":"Differences in gene expression and gene associations in epicardial fat compared to subcutaneous fat","volume":"49","author":"Yim","year":"2017","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0116","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1161\/01.CIR.0000099542.57313.C5","article-title":"Human epicardial adipose tissue is a source of inflammatory mediators","volume":"108","author":"Mazurek","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0117","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.regpep.2010.07.169","article-title":"Greater expression of inflammatory cytokines, adrenomedullin, and natriuretic peptide receptor-C in epicardial adipose tissue in coronary artery disease","volume":"165","author":"Shibasaki","year":"2010","journal-title":"Regul Pept"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0118","doi-asserted-by":"crossref","first-page":"e99495","DOI":"10.1371\/journal.pone.0099495","article-title":"Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology","volume":"9","author":"Putko","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0119","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1248\/bpb.b18-00363","article-title":"IL-1\u03b2 plays an important role in pressure overload-induced atrial fibrillation in mice","volume":"42","author":"Matsushita","year":"2019","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0120","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/CIRCULATIONAHA.118.035202","article-title":"Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation","volume":"138","author":"Yao","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0121","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1253\/circj.CJ-12-1155","article-title":"Role of tumor necrosis factor-\u03b1 in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate","volume":"77","author":"Liew","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0122","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1084\/jem.20171274","article-title":"Cardiac macrophages promote diastolic dysfunction","volume":"215","author":"Hulsmans","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0123","doi-asserted-by":"crossref","first-page":"e68893","DOI":"10.1371\/journal.pone.0068893","article-title":"Interleukin-16 promotes cardiac fibrosis and myocardial stiffening in heart failure with preserved ejection fraction","volume":"8","author":"Tamaki","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0124","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1210\/en.2013-2065","article-title":"5TNF-\u03b1 and IL-1\u03b2 neutralization ameliorates angiotensin II-induced cardiac damage in male mice","volume":"155","author":"Wang","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0125","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1210\/endo-125-6-3084","article-title":"Tumor necrosis factor and interleukin-1 are potent inhibitors of angiotensin-II-induced aldosterone synthesis","volume":"125","author":"Natarajan","year":"1989","journal-title":"Endocrinology"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0126","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.amjmed.2003.09.039","article-title":"Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy","volume":"116","author":"Wolfe","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0127","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjcard.2013.08.047","article-title":"Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)","volume":"113","author":"Van Tassell","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0128","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005036","article-title":"IL-1 blockade in patients with heart failure with preserved ejection fraction","volume":"11","author":"Van Tassell","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0129","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0130","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0131","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0132","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/876049","article-title":"Therapeutic implications of PPARgamma in cardiovascular diseases","volume":"2010","author":"Hasegawa","year":"2010","journal-title":"PPAR Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0133","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.1417232112","article-title":"Adipogenesis and epicardial adipose tissue: a novel fate of the epicardium induced by mesenchymal transformation and PPAR\u03b3 activation","volume":"112","author":"Yamaguchi","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0134","first-page":"428","article-title":"Adiponectin promotes preadipocyte differentiation via the PPAR\u03b3 pathway","volume":"17","author":"Yang","year":"2018","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0135","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000492875","article-title":"Targeting peroxisome proliferator activated receptor \u03b1 (PPAR \u03b1) for the prevention of mitochondrial impairment and hypertrophy in cardiomyocytes","volume":"49","author":"Kar","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0136","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1271\/bbb.120423","article-title":"The PPAR\u03b3 agonist protects cardiomyocytes from oxidative stress and apoptosis via thioredoxin overexpression","volume":"76","author":"Kim","year":"2012","journal-title":"Biosci Biotechnol Biochem"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0137","first-page":"1712","article-title":"Influence of phenotype conversion of epicardial adipocytes on the coronary atherosclerosis and its potential molecular mechanism","volume":"7","author":"Wang","year":"2015","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0138","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1161\/CIRCRESAHA.115.307856","article-title":"Mutual Regulation of epicardial adipose tissue and myocardial redox state by PPAR-\u03b3\/adiponectin signalling","volume":"118","author":"Antonopoulos","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0139","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1758-5996-6-47","article-title":"Synergistic anti-inflammatory effect: simvastatin and pioglitazone reduce inflammatory markers of plasma and epicardial adipose tissue of coronary patients with metabolic syndrome","volume":"6","author":"Grosso","year":"2014","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0140","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2337\/dc10-2083","article-title":"Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone","volume":"34","author":"Sacks","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0141","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1210\/jc.2009-1441","article-title":"Pioglitazone compared with metformin increases pericardial fat volume in patients with type 2 diabetes mellitus","volume":"95","author":"Jonker","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0142","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.2337\/db07-0924","article-title":"Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis","volume":"57","author":"Caglayan","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0143","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1161\/01.CIR.0000039346.31538.2C","article-title":"Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction","volume":"106","author":"Shiomi","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0144","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/MEG.0b013e3283608317","article-title":"Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin","volume":"25","author":"Maffioli","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0145","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1262-3636(07)70273-2","article-title":"Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia","volume":"32","author":"Yin","year":"2006","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0146","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000441","article-title":"The peroxisome proliferator activated receptor-\u03b3 pioglitazone improves vascular function and decreases disease activity in patients with rheumatoid arthritis","volume":"2","author":"Marder","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0147","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1080\/09546634.2018.1544702","article-title":"Efficacy and safety of pioglitazone plus phototherapy vs. phototherapy in patients with plaque type psoriasis: a double blinded randomized controlled trial","volume":"30","author":"Ghiasi","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0148","doi-asserted-by":"crossref","first-page":"e31516","DOI":"10.1371\/journal.pone.0031516","article-title":"Pioglitazone decreases hepatitis C viral load in overweight, treatment na\u00efve, genotype 4 infected-patients: a pilot study","volume":"7","author":"Chojkier","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0149","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00011-005-0002-8","article-title":"Attenuation of experimental colonic injury by thiazolidinedione agents","volume":"55","author":"Takaki","year":"2006","journal-title":"Inflamm Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yjmcc.2013.09.016","article-title":"Beneficial effects of pioglitazone on atrial structural and electrical remodeling in vitro cellular models","volume":"65","author":"Gu","year":"2013","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0151","doi-asserted-by":"crossref","first-page":"e12284","DOI":"10.1111\/1755-5922.12284","article-title":"Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits","volume":"35","author":"Liu","year":"2017","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0152","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.hrthm.2007.12.010","article-title":"Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure","volume":"5","author":"Shimano","year":"2008","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0153","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.hrthm.2010.10.029","article-title":"Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats","volume":"8","author":"Kume","year":"2011","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0154","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1540-8167.2011.02186.x","article-title":"PPAR-\u03b3 activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model","volume":"23","author":"Xu","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0155","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/FJC.0000000000000397","article-title":"Activation of peroxisome proliferator-activated receptor \u03b3 prevents development of heart failure with preserved ejection fraction; inhibition of Wnt-\u03b2-catenin signaling as a possible mechanism","volume":"68","author":"Kamimura","year":"2016","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0156","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ijcard.2014.11.099","article-title":"Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome","volume":"179","author":"Matsuura","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0157","first-page":"140","article-title":"Thiazolidinediones are associated with a decreased risk of atrial fibrillation compared with other antidiabetic treatment: a nationwide cohort study","volume":"3","author":"Pallisgaard","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0158","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/europace\/eur131","article-title":"Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus","volume":"13","author":"Gu","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0159","first-page":"401","article-title":"Pioglitazone improves ventricular diastolic function in patients with diabetes mellitus: a tissue Doppler study","volume":"65","author":"Ordu","year":"2010","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0160","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1161\/CIRCULATIONAHA.108.803916","article-title":"Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus","volume":"119","author":"van der Meer","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0161","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/646423","article-title":"Thiazolidinediones and edema: recent advances in the pathogenesis of thiazolidinediones-induced renal sodium retention","volume":"2015","author":"Horita","year":"2015","journal-title":"PPAR Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0162","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.metabol.2010.02.010","article-title":"Fluid compartmental shifts with efficacious pioglitazone therapy in overweight monkeys: implications for peroxisome proliferator-activated receptor-gamma agonist use in prediabetes","volume":"59","author":"Kavanagh","year":"2010","journal-title":"Metabolism"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0163","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1475-2840-8-15","article-title":"Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes","volume":"8","author":"Dorkhan","year":"2009","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0164","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00592-007-0014-7","article-title":"Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes","volume":"45","author":"Sambanis","year":"2008","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0165","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1210\/jc.2002-021765","article-title":"Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone","volume":"88","author":"Ogawa","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0166","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12872-017-0531-4","article-title":"Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis","volume":"17","author":"Zhang","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0167","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/11587580-000000000-00000","article-title":"Thiazolidine-diones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials","volume":"11","author":"Hernandez","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0168","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0169","doi-asserted-by":"crossref","first-page":"e65600","DOI":"10.5812\/ijem.65600","article-title":"Insulin monotherapy versus insulin combined with other glucose-lowering agents in type 2 diabetes: a narrative review","volume":"16","author":"Abdi","year":"2018","journal-title":"Int J Endocrinol Metab"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0170","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1210\/jc.2009-1974","article-title":"Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19)","volume":"95","author":"Charbonnel","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0171","doi-asserted-by":"crossref","first-page":"e6112","DOI":"10.1371\/journal.pone.0006112","article-title":"Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis","volume":"4","author":"Clar","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0172","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/CIRCULATIONAHA.118.034763","article-title":"Heart failure after ischemic stroke or transient ischemic attack in insulin-resistant patients without diabetes mellitus treated with pioglitazone","volume":"138","author":"Young","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0173","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijcard.2011.05.056","article-title":"A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular dis-ease: an analysis of the PROactive study","volume":"162","author":"Pfister","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0174","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cardfail.2008.02.007","article-title":"Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction","volume":"14","author":"Giles","year":"2008","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0175","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/CIRCRESAHA.116.308445","article-title":"Anti-inflammatory effects of metformin irrespective of diabetes status","volume":"119","author":"Cameron","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0176","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/cbf.3367","article-title":"Metformin inhibits pro-inflammatory responses via targeting nuclear factor-\u03baB in HaCaT cells","volume":"37","author":"Ba","year":"2019","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0177","doi-asserted-by":"crossref","first-page":"5","DOI":"10.23937\/2469-5726\/1510005","article-title":"Suppression of experimental arthritis through AMP-activated protein kinase activation and autophagy modulation","volume":"1","author":"Yan","year":"2015","journal-title":"J Rheum Dis Treat"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0178","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12895-016-0049-y","article-title":"Randomized placebo control study of insulin sensitizers (metformin and pioglitazone) in psoriasis patients with metabolic syndrome (topical treatment cohort)","volume":"16","author":"Singh","year":"2016","journal-title":"BMC Dermatol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0179","article-title":"Metformin ameliorates inflammatory bowel disease by suppression of the STAT3 signaling pathway and regulation of the between Th17\/Treg balance","volume":"10","author":"Lee","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0180","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1042\/CS20180167","article-title":"Metformin inhibits inflammatory signals in the gut by controlling AMPK and p38 MAP kinase activation","volume":"132","author":"Di Fusco","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0181","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1016\/j.ijid.2012.02.004","article-title":"The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance","volume":"16","author":"Yu","year":"2012","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0182","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.mce.2017.09.025","article-title":"Metformin improves obesity-associated inflammation by altering macrophages polarization","volume":"461","author":"Jing","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0183","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.cellsig.2016.06.018","article-title":"Metformin and res-veratrol ameliorate muscle insulin resistance through preventing lipolysis and inflammation in hypoxic adipose tissue","volume":"28","author":"Zhao","year":"2016","journal-title":"Cell Signal"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0184","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1152\/japplphysiol.00936.2012","article-title":"Effects of endurance exercise training, metformin, and their combination on adipose tissue leptin and IL-10 secretion in OLETF rats","volume":"113","author":"Jenkins","year":"2012","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0185","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000324582","article-title":"In vitro and in vivo effects of metformin on human adipose tissue adiponectin","volume":"4","author":"Zulian","year":"2011","journal-title":"Obes Facts"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0186","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1475-2840-12-150","article-title":"Activin A is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes","volume":"12","author":"Chen","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0187","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10735-018-9801-4","article-title":"Favorable outcomes of metformin on coronary microvasculature in experimental diabetic cardiomyopathy","volume":"49","author":"Abdel-Hamid","year":"2018","journal-title":"J Mol Histol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0188","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/1440-1681.12622","article-title":"Exacerbated cardiac fibrosis induced by \u03b2-adrenergic activation in old mice due to decreased AMPK activity","volume":"43","author":"Wang","year":"2016","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0189","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.yjmcc.2016.07.006","article-title":"Metformin inhibits aldosterone-induced cardiac fibroblast activation, migration and proliferation in vitro, and reverses aldosterone+salt-induced cardiac fibrosis in vivo","volume":"98","author":"Mummidi","year":"2016","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0190","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ijcard.2011.09.012","article-title":"Cardiac fibrosis and vascular remodeling are attenuated by metformin in obese rats","volume":"165","author":"Burl\u00e1","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0191","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1440-1681.2010.05461.x","article-title":"Metformin attenuates ventricular hypertrophy by activating the AMP-activated protein kinase-endothelial nitric oxide synthase pathway in rats","volume":"38","author":"Zhang","year":"2011","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0192","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cvr\/cvq066","article-title":"Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway","volume":"87","author":"Xiao","year":"2010","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0193","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12872-018-0805-5","article-title":"Metform-in restores electrophysiology of small conductance calcium-activated potassium channels in the atrium of GK diabetic rats","volume":"18","author":"Fu","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0194","doi-asserted-by":"crossref","first-page":"3","DOI":"10.15171\/bi.2015.02","article-title":"Metformin attenuates myocardial remodeling and neutrophil recruitment after myocardial infarction in rat","volume":"5","author":"Soraya","year":"2015","journal-title":"Bioimpacts"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0195","doi-asserted-by":"crossref","first-page":"H459","DOI":"10.1152\/ajpheart.00054.2011","article-title":"Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure","volume":"301","author":"Yin","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0196","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1161\/CIRCULATIONAHA.108.798561","article-title":"Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase","volume":"119","author":"Sasaki","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0197","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2337\/db11-1132","article-title":"Metformin prevents the development of chronic heart failure in the SHHF rat model","volume":"61","author":"Cittadini","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0198","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.taap.2018.10.004","article-title":"Metformin attenuates cardiovascular and renal injury in uninephrectomized rats on DOCA-salt: involvement of AMPK and miRNAs in cardioprotection","volume":"362","author":"Amara","year":"2019","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0199","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4244\/EIJY15M03_09","article-title":"Coronary microvascular function in patients with type 2 diabetes mellitus","volume":"11","author":"Leung","year":"2016","journal-title":"EuroIntervention"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0200","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-10-0624","article-title":"Metformin is associated with improved left ventricular diastolic function measured by tissue Doppler imaging in patients with diabetes","volume":"163","author":"Andersson","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0201","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/107424849800300407","article-title":"Effects of metformin on collagen glycation and diastolic dysfunction in diabetic myocardium","volume":"3","author":"Jyothirmayi","year":"1998","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0202","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12933-014-0123-x","article-title":"Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies","volume":"13","author":"Chang","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0203","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005379","article-title":"Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: a cohort study","volume":"6","author":"Roumie","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0204","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1471-2261-14-129","article-title":"The risk of heart failure assoc-iated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies","volume":"14","author":"Varas-Lorenzo","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0205","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00592-008-0090-3","article-title":"The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis","volume":"46","author":"Pantalone","year":"2009","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0206","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1007\/s00125-010-1906-6","article-title":"Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study","volume":"53","author":"Andersson","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0207","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2459\/JCM.0000000000000420","article-title":"Metformin and risk of long-term mortality following an admission for acute heart failure","volume":"18","author":"F\u00e1cila","year":"2017","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0208","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","article-title":"Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients","volume":"6","author":"Eurich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0209","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ijcard.2011.10.141","article-title":"Metformin therapy and prognosis of patients with heart failure and new-onset diabetes mellitus: a propens-ity-matched study in the community","volume":"166","author":"Romero","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0210","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1161\/CIRCHEARTFAILURE.110.952556","article-title":"Metformin use and mortality in ambulatory patients with diabetes and heart failure","volume":"4","author":"Aguilar","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0211","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2337\/diacare.28.10.2345","article-title":"Improved clinical outcomes associated with metformin in patients with diabetes and heart failure","volume":"28","author":"Eurich","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0212","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.diabres.2017.12.011","article-title":"Is metformin beneficial for heart failure in patients with type 2 diabetes?","volume":"136","author":"Packer","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0213","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","article-title":"SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice","volume":"292","author":"Wang","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0214","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes: further augmentation of the effects with saxagliptin, a DPP4 inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0215","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10557-018-6778-x","article-title":"Combined SGLT2 and DPP4 inhibition reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic nephropathy in mice with type 2 diabetes","volume":"32","author":"Birnbaum","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0216","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1038\/s41598-018-23420-4","article-title":"Canagliflozin inhibits interleukin-1\u03b2-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms","volume":"8","author":"Mancini","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0217","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bcp.2018.03.013","article-title":"Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells","volume":"152","author":"Xu","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0218","doi-asserted-by":"crossref","first-page":"16113","DOI":"10.1038\/s41598-018-34305-x","article-title":"A reduced M1-like\/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition","volume":"8","author":"Miyachi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0219","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0220","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/cvr\/cvx186","article-title":"Novel effects of dapagliflozin on epicardial adipose tissue with insulin resistance, high levels of inflammatory chemokines production and low differentiation ability","volume":"114","author":"D\u00edaz-Rodr\u00edguez","year":"2017","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0221","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","article-title":"Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome","volume":"15","author":"Kusaka","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0222","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-019-0849-6","article-title":"The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats","volume":"18","author":"Lee","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0223","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0224","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0225","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","article-title":"Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome","volume":"15","author":"Kusaka","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0226","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","article-title":"Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes","volume":"16","author":"Habibi","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0227","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jacbts.2017.07.003","article-title":"Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure","volume":"2","author":"Byrne","year":"2017","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0228","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0229","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13098-017-0275-4","article-title":"Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus","volume":"9","author":"Yagi","year":"2017","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0230","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s13300-017-0279-y","article-title":"Ipragliflozin reduces epicardial fat accumulation in non-obese type 2 diabetic patients with visceral obesity: a pilot study","volume":"8","author":"Fukuda","year":"2017","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0231","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/cvr\/cvx186","article-title":"Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability","volume":"114","author":"D\u00edaz-Rodr\u00edguez","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0232","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","article-title":"Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure","volume":"17","author":"Soga","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0233","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/2047487318755531","article-title":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis","volume":"25","author":"Usman","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0234","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0235","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0236","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1161\/CIRCULATIONAHA.119.040057","article-title":"Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes: results from the CANVAS program","volume":"139","author":"Figtree","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0237","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","article-title":"Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction","volume":"21","author":"Yurista","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0238","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/cvr\/cvz004","article-title":"Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts","volume":"115","author":"Uthman","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0239","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0240","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0241","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s13075-017-1431-9","article-title":"Incretins in patients with rheumatoid arthritis","volume":"19","author":"Tejera-Segura","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0242","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1530\/JME-18-0129","article-title":"TNF signaling impacts glucagon-like peptide-1 expression and secretion","volume":"61","author":"Chen","year":"2018","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0243","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0244","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.intimp.2014.07.010","article-title":"Glucagon like peptide-1 attenuates bleomycin-induced pulmonary fibrosis, involving the inactivation of NF-\u03baB in mice","volume":"22","author":"Gou","year":"2014","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0245","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1007\/s12035-017-0550-2","article-title":"Activation of glucagon-like peptide-1 receptor promotes neuropro-tection in experimental autoimmune encephalomyelitis by reducing neuroinflammatory responses","volume":"55","author":"Lee","year":"2018","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0246","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40360-017-0172-3","article-title":"Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells","volume":"18","author":"Chang","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0247","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/ket255","article-title":"From endocrine to rheumatism: do gut hormones play roles in rheumatoid arthritis?","volume":"53","author":"Chen","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0248","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.diabres.2019.03.002","article-title":"Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study","volume":"150","author":"Xu","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0249","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.3389\/fimmu.2017.01734","article-title":"Role of incretin axis in inflammatory bowel disease","volume":"8","author":"Duan","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0250","doi-asserted-by":"crossref","first-page":"e12317","DOI":"10.1111\/1755-5922.12317","article-title":"Exenatide exhibits anti-inflammatory properties and modulates endothelial response to tumor necrosis factor \u03b1-mediated activation","volume":"36","author":"Garczorz","year":"2018","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0251","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE-\/- and LDLr-\/- mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0252","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.4103\/0366-6999.170259","article-title":"Exenatide reduces tumor necrosis factor-\u03b1-induced apoptosis in cardiomyocytes by alleviating mitochondrial dysfunction","volume":"128","author":"Cao","year":"2015","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0253","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00210-017-1414-z","article-title":"Liraglutide ameliorates cardiotoxicity induced by doxorubicin in rats through the Akt\/GSK-3\u03b2 signaling pathway","volume":"390","author":"Abbas","year":"2017","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0254","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1042\/CS20160061","article-title":"Modulation of myocardial injury and collagen deposition following ischaemia-reperfusion by linagliptin and liraglutide, and both together","volume":"130","author":"Wang","year":"2016","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-015-0518-1","article-title":"Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages","volume":"111","author":"Tate","year":"2016","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0256","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00395-015-0476-7","article-title":"Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix","volume":"110","author":"Robinson","year":"2015","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0257","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.yjmcc.2014.08.022","article-title":"Exendin-4 improves cardiac function in mice overexpressing monocyte chemoattractant protein-1 in cardiomyocytes","volume":"76","author":"Younce","year":"2014","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0258","first-page":"4499","article-title":"Liraglutide suppresses proliferation and induces adipogenic differentiation of 3T3-L1 cells via the Hippo-YAP signaling pathway","volume":"17","author":"Li","year":"2018","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0259","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3390\/jcm8040479","article-title":"GLP-1 limits adipocyte inflammation and its low circulating pre-operative concentrations predict worse type 2 diabetes remission after bariatric surgery in obese patients","volume":"8","author":"Izaguirre","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0260","article-title":"Exendin-4 upregulates adiponectin level in adipocytes via Sirt1\/Foxo-1 signaling pathway","volume":"12","author":"Wang","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0261","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijcard.2019.04.039","article-title":"Epicardial adipose tissue GLP-1 receptor is associated with genes involved in fatty acid oxidation and white-to-brown fat differentiation: a target to modulate cardiovascular risk?","volume":"292","author":"Dozio","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0262","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/oby.21718","article-title":"Liraglutide causes large and rapid epicardial fat reduction","volume":"25","author":"Iacobellis","year":"2017","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0263","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/dom.12680","article-title":"Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy","volume":"18","author":"Dutour","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0264","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00380-018-01327-4","article-title":"Liraglutide suppresses atrial electrophysiological changes","volume":"34","author":"Nakamura","year":"2019","journal-title":"Heart Vessels"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0265","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.112.091215","article-title":"A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity","volume":"127","author":"Noyan-Ashraf","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0266","doi-asserted-by":"crossref","first-page":"H295","DOI":"10.1152\/ajpheart.00990.2012","article-title":"Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes","volume":"305","author":"Monji","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0267","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/1479164115605000","article-title":"Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis","volume":"13","author":"Gaspari","year":"2016","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0268","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.peptides.2018.05.009","article-title":"Effect of the peptides relaxin, neuregulin, ghrelin and glucagon-like peptide-1, on cardiomyocyte factors involved in the molecular mechanisms leading to diastolic dysfunction and\/or heart failure with preserved ejection fraction","volume":"111","author":"Warbrick","year":"2019","journal-title":"Peptides"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0269","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12265-018-9795-z","article-title":"GLP-1 improves diastolic function and survival in heart failure with preserved ejection fraction","volume":"11","author":"Nguyen","year":"2018","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0270","doi-asserted-by":"crossref","first-page":"e13007","DOI":"10.1111\/eci.13007","article-title":"Liraglutide relieves cardiac dilated function than DPP-4 inhibitors","volume":"48","author":"Hiramatsu","year":"2018","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0271","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3389\/fendo.2017.00325","article-title":"Effects on subclinical heart failure in type 2 diabetic subjects on liraglutide treatment vs. glimepiride both in combination with metformin: a randomized open parallel-group study","volume":"8","author":"Nystr\u00f6m","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0272","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/dom.12900","article-title":"Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: a randomized double-blind placebo-controlled clinical trial","volume":"19","author":"J\u00f8rgensen","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0273","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jdiacomp.2016.10.003","article-title":"Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes","volume":"31","author":"Scalzo","year":"2017","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0274","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.yjmcc.2015.09.018","article-title":"Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium","volume":"89","author":"Wallner","year":"2015","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0275","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.2337\/db16-1206","article-title":"Glucagon-like peptide 1 receptor activation augments cardiac output and improves cardiac efficiency in obese swine after myocardial infarction","volume":"66","author":"Sassoon","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0276","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1161\/01.CIR.0000139339.85840.DD","article-title":"Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy","volume":"110","author":"Nikolaidis","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0277","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S2213-8587(15)00233-8","article-title":"Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis","volume":"3","author":"Fisher","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0278","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/CIRCINTERVENTIONS.110.960476","article-title":"A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans","volume":"4","author":"Read","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0279","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","article-title":"Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure","volume":"12","author":"Sokos","year":"2006","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0280","doi-asserted-by":"crossref","first-page":"62693","DOI":"10.18632\/oncotarget.18570","article-title":"Effects of liraglutide on hemodynamic parameters in patients with heart failure","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0281","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s12020-016-1166-4","article-title":"Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure","volume":"57","author":"Arturi","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0282","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0283","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0284","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0285","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0286","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0287","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12933-017-0648-x","article-title":"Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines","volume":"17","author":"Packer","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0288","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1161\/CIRCRESAHA.118.312673","article-title":"Do DPP-4 inhibitors cause heart failure events by promoting adrenergically mediated cardiotoxicity? Clues from laboratory models and clinical trials","volume":"122","author":"Packer","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0289","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2337\/db15-1224","article-title":"Inhibition of dipeptidyl peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat-fed diabetic mice","volume":"65","author":"Mulvihill","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0290","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jchf.2017.12.016","article-title":"Worsening heart failure during the use of DPP-4 inhibitors: pathophysiological mechanisms, clinical risks, and potential influence of concomitant antidiabetic medications","volume":"6","author":"Packer","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0291","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005945","article-title":"Alogliptin, a dipeptidyl peptidase-4 inhibitor, alleviates atrial remodeling and improves mitochondrial function and biogenesis in diabetic rabbits","volume":"6","author":"Zhang","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0292","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.hrthm.2015.03.010","article-title":"Alogliptin, a dipeptidyl peptidase-4 inhibitor, regulates the atrial arrhythmogenic substrate in rabbits","volume":"12","author":"Yamamoto","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0293","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12933-017-0640-5","article-title":"Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan","volume":"16","author":"Chang","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0294","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197245","article-title":"Antihyperglycemic drugs use and new-onset atrial fibrillation: a population-based nested case control study","volume":"13","author":"Liou","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0295","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/dom.13512","article-title":"Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies","volume":"21","author":"Bell","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0296","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/cvr\/cvu223","article-title":"Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4","volume":"104","author":"Hamdani","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0297","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.metabol.2014.04.002","article-title":"Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity","volume":"63","author":"Bostick","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0298","doi-asserted-by":"crossref","first-page":"i610","DOI":"10.1136\/bmj.i610","article-title":"Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies","volume":"352","author":"Li","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0299","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jchf.2017.08.004","article-title":"Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial","volume":"6","author":"McMurray","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0300","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0301","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jamacardio.2016.0103","article-title":"Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial","volume":"1","author":"McGuire","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0302","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0303","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/CIRCULATIONAHA.118.038352","article-title":"Linagliptin effects on heart failure and re-lated outcomes in individuals with type 2 diabetes mellitus at high cardio-vascular and renal risk in CARMELINA","volume":"139","author":"McGuire","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0304","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1007\/s00125-014-3237-5","article-title":"CXCL12 secreted from adipose tissue recruits macrophages and induces insulin resistance in mice","volume":"57","author":"Kim","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0305","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12020-015-0710-y","article-title":"Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study","volume":"51","author":"Lima-Mart\u00ednez","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0306","doi-asserted-by":"crossref","unstructured":"Koska J, Osredkar T, D'Souza K, Sands M, Sinha S, Zhang W, Meyer C, Reaven PD. Effects of saxagliptin on adipose tissue inflammation and vascular function in overweight and obese people: a placebo-controlled study [e-pub ahead of print]. Diabet Med. doi:10.1111\/dme.13889. accessed September 2019.","DOI":"10.1111\/dme.13889"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0307","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10557-018-06850-0","article-title":"Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): are the \u201ccardiac benefits\u201d of empagliflozin independent of its hypoglycemic activity?","volume":"33","author":"Santos-Gallego","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cardfail.2019.09.002_bib0308","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12933-017-0615-6","article-title":"Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial","volume":"16","author":"Natali","year":"2017","journal-title":"Cardiovasc Diabetol"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916419305299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916419305299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:43:13Z","timestamp":1761028993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916419305299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":308,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1071916419305299"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2019.09.002","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2019.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}